advertisement
Abstract #5410 Published in IGR 1-2
Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open- angle glaucoma
Konstas AGP; Maltezos AC; Gandi S; Hudgins AC; Stewart WCAmerican Journal of Ophthalmology 1999; 128: 15-20
PURPOSE: To compare the 24-hour diurnal ocular hypotensive efficacy of two dosing regimens of latanoprost, once daily (8 AM or 10 PM), vs timolol maleate, twice daily. METHODS: We measured six diurnal intraocular pressure curves (6 AM, 10 AM, 2 PM, 6 PM, 10 PM, and 2 AM) in one randomly selected eye of 34 Greek patients newly diagnosed with primary open-angle glaucoma. The first diurnal curve was an untreated baseline. Patients began taking timolol 0.5%, twice daily, for 2 months. Patients were randomly assigned to latanoprost 0.005% given at 8 AM or 10 PM for I month and then changed to the other dosing regimen for I month. A diurnal curve was performed after each dosing period. RESULTS: The baseline diurnal pressure for all 34 subjects was 23.1 +- 3.7 mmHg. The average intraocular pressures at 6 AM for patients who were given latanoprost in the evening (17.9 +- 2.9 mmHg) was statistically lower than that in patients given timolol solution (20.1 +- 2.5 mmHg, P = .003); however, patients who were given timolol demonstrated a similar diurnal intraocular pressure (19.1 +- 2.8 mmHg) to both morning (18.8 +- 3.7 mmHg) and evening doses (18.8 +- 3.6 mmHg) of latanoprost (P =.329). When the two latanoprost dosages were compared directly, evening administration provided a statistically lower intraocular pressure at 10 AM (P = .0001) and morning administration at 10 PM (P = .0001). This study had an 80% power to exclude a 1.2-mmHg difference between groups. CONCLUSIONS: This study indicates that in a small population, both latanoprost and timolol are effective in lowering intraocular pressure throughout a 24-hour period; however, latanoprost is most effective in the 12-hour to 24-hour period after administration.
Dr. W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum St, Charleston, SC 29412-2464; United States
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
